Stock Analiz

Aurora Cannabis Inc. ACB

Medicinal Chemicals and Botanical Products · data as of November 13, 2026

$4.94Market cap $325M
Open the interactive analysis →

Aurora Cannabis Inc. (ACB) is a healthcare company listed in the US with a market value of about $325M. In the twelve months to September 30, 2026 it had revenue of $225M and net income of -$62M, a net margin of -27.4%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -15%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.

About Aurora Cannabis

Aurora Cannabis is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $42M in 2018 to $225M in 2026, growth of about 23.4% a year. It was profitable in 2 of the last 8 years in our data. Its share count fell by 14% over three years (buybacks).

Score: 0.6 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.4
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-5.5%
Shareholder yield0.0%
Intrinsic value vs. price−81%

Growth and quality

Revenue growth (1 yr)20.3%
Revenue growth (5 yrs, per year)5.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-461.0%
ROIC (5-yr avg.)-14.9%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20262025202420222021202020192018
Revenue$225M$225M$239M$199M$171M$198M$196M$188M$42M
Net income-$62M-$95M$1M-$51M-$1.3B-$559M-$2.4B-$224M$54M
Free cash flow-$18M-$25M-$2M-$63M-$110M-$213M—-$463M-$165M
EPS (diluted)$-1.02$-1.68$0.02$-0.78$-20.21$-8.50$-36.49$-3.41$0.83
Net margin-27.4%-42.4%0.5%-25.7%-776.0%-282.2%-1221.7%-119.5%130.3%
ROIC——0.6%-7.2%-34.9%-13.8%-19.3%-6.4%-5.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Aurora Cannabis stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Aurora Cannabis pay a dividend?

Not currently.

Is Aurora Cannabis a good stock to buy?

We do not give buy or sell advice. Aurora Cannabis scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.